The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are:
Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis.
Participants will:
Take the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights
None
None
Parallel
Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
DrugAnticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis
Desmopressin (DDAVP)
DrugADH analogue in treatment of mono-symptomatic nocturnal enuresis
Percentage of improvement in number of wet nights per week
Counting number of wet nights per week before and after receiving treatment and the resulting percentage will be the primary end point.
Number of patients who experienced side effects in response to each treatment.
Each patient will be followed up monthly during the 3 months period and surveyed for side effects. The number of patients who experienced side effects will be compared between the two groups and compare the number of patients who subsequently discontinued the treatment.
Click on the lead sponsor to view all of their trials.
